Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EQ 
Equillium Inc (EQ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: EQ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $1
1 Year Target Price $1
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.89% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.07M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 2 | Beta 1.95 | 52 Weeks Range 0.27 - 1.50 | Updated Date 06/29/2025 |
52 Weeks Range 0.27 - 1.50 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -46% | Operating Margin (TTM) -47.19% |
Management Effectiveness
Return on Assets (TTM) -29.73% | Return on Equity (TTM) -88.32% |
Valuation
Trailing PE - | Forward PE 1.53 | Enterprise Value -2591079 | Price to Sales(TTM) 0.36 |
Enterprise Value -2591079 | Price to Sales(TTM) 0.36 | ||
Enterprise Value to Revenue 0.01 | Enterprise Value to EBITDA 0.07 | Shares Outstanding 35719300 | Shares Floating 18292219 |
Shares Outstanding 35719300 | Shares Floating 18292219 | ||
Percent Insiders 35.9 | Percent Institutions 19.14 |
Analyst Ratings
Rating 2 | Target Price 1 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Equillium Inc
Company Overview
History and Background
Equillium, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory diseases. Founded in 2017, they are developing itolizumab, a novel anti-CD6 monoclonal antibody.
Core Business Areas
- Therapeutic Development: Focuses on the research, development, and clinical trials of itolizumab for autoimmune and inflammatory diseases.
Leadership and Structure
Bruce Steel serves as CEO. The company has a board of directors and is structured around research, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- Itolizumab (EQ001): A novel anti-CD6 monoclonal antibody being developed for various autoimmune and inflammatory diseases, including acute graft-versus-host disease (aGVHD), lupus nephritis, and uncontrolled asthma. No current market share as it is still in clinical trials. Competitors include companies developing treatments for these specific indications, such as established immunosuppressants and other biologics (e.g., those by Novartis, Roche, and others).
Market Dynamics
Industry Overview
The autoimmune and inflammatory disease market is a large and growing sector with unmet medical needs. The space is heavily researched with pharmaceutical companies and Biotech companies vying for market share by developing new therapies.
Positioning
Equillium aims to address unmet needs in severe autoimmune and inflammatory diseases with itolizumab, targeting the CD6 pathway. Their competitive advantage lies in the novel mechanism of action of itolizumab.
Total Addressable Market (TAM)
The TAM for autoimmune and inflammatory disease therapies is estimated to be over $100 billion globally. Equillium is targeting niche indications within this broader market, positioning them to potentially capture a significant share if itolizumab is successful in clinical trials and approved.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action (anti-CD6)
- Potential for treating a range of autoimmune and inflammatory diseases
- Experienced management team
- Orphan drug designation for certain indications
Weaknesses
- Single product pipeline (itolizumab)
- Reliance on clinical trial success
- Limited financial resources compared to larger pharmaceutical companies
- Lack of established market presence
Opportunities
- Successful clinical trial outcomes
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Regulatory approvals for itolizumab
Threats
- Clinical trial failures
- Competition from existing and new therapies
- Regulatory hurdles
- Patent expirations
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- NVS
- RHHBY
- LLY
Competitive Landscape
Equillium faces competition from established pharmaceutical companies with approved therapies for autoimmune and inflammatory diseases. Their advantage lies in their novel anti-CD6 mechanism.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily tied to advancements in clinical trials and securing funding.
Future Projections: Future growth depends heavily on the success of itolizumab in clinical trials and subsequent regulatory approvals. Analyst estimates would be available on financial data sources.
Recent Initiatives: Focus on advancing clinical trials for aGVHD, lupus nephritis, and uncontrolled asthma and strategic partnership for funding these studies.
Summary
Equillium is a clinical-stage biotech company focusing on itolizumab for autoimmune diseases. Its success hinges on positive clinical trial outcomes. The company faces challenges due to its limited product pipeline and competition from larger pharmaceutical firms. However, successful trials and strategic partnerships could unlock significant growth potential. The anti-CD6 mechanism is unique and if proven effective it could capture significant market share
Peer Comparison
Sources and Disclaimers
Data Sources:
- Equillium Inc. website
- SEC filings
- Company press releases
- Analyst reports (if available)
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Market share estimates are approximate and may vary. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Equillium Inc
Exchange NASDAQ | Headquaters La Jolla, CA, United States | ||
IPO Launch date 2018-10-11 | Co-Founder, President, CEO & Director Mr. Bruce D. Steel C.F.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | Website https://www.equilliumbio.com |
Full time employees 35 | Website https://www.equilliumbio.com | ||
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.